Literature DB >> 15845897

PF4/heparin complexes are T cell-dependent antigens.

Shayela Suvarna1, Lubica Rauova, Emily K E McCracken, Christina M Goss, Bruce S Sachais, Steven E McKenzie, Michael P Reilly, Michael Dee Gunn, Douglas B Cines, Mortimer Poncz, Gowthami Arepally.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a life-threatening, thrombotic disorder associated with development of anti-platelet factor 4 (anti-PF4)/heparin autoantibodies. Little is known about the antigenic and cellular requirements that initiate the immune response to these complexes. To begin to delineate mechanisms of autoantibody formation in HIT, we studied the immunizing effects of murine PF4 (mPF4)/heparin in mice with and without thymic function. Euthymic mice were injected with mPF4/heparin complexes, mPF4, heparin, or buffer. Mice injected with mPF4/heparin, but not mPF4 or heparin alone, developed heparin-dependent autoantibodies that shared serologic and functional characteristics of human HIT antibodies, including preferential binding to mPF4/heparin complexes and causing heparin- and FcRgammaIIA-dependent platelet activation. In contrast, athymic mice did not develop HIT-like antibodies. Taken together, these studies establish that PF4/heparin complexes are highly immunogenic and elicit self-reacting anti-PF4/heparin antibodies in a T cell-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845897      PMCID: PMC1895158          DOI: 10.1182/blood-2004-12-4955

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia.

Authors:  G A Denomme; T E Warkentin; P Horsewood; J A Sheppard; M N Warner; J G Kelton
Journal:  J Lab Clin Med       Date:  1997-09

Review 2.  Platelet factor 4: production, structure, and physiologic and immunologic action.

Authors:  M B Zucker; I R Katz
Journal:  Proc Soc Exp Biol Med       Date:  1991-11

3.  Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and FC fragments on antibody-heparin-platelet interaction.

Authors:  B H Chong; P A Castaldi; M C Berndt
Journal:  Thromb Res       Date:  1989-07-15       Impact factor: 3.944

4.  Characterization of the humoral immune response in heparin-induced thrombocytopenia.

Authors:  J S Suh; M I Malik; R H Aster; G P Visentin
Journal:  Am J Hematol       Date:  1997-03       Impact factor: 10.047

5.  Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; S E McKenzie; X M Jiang; M Poncz; D B Cines
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

6.  Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay.

Authors:  R I Handin; M McDonough; M Lesch
Journal:  J Lab Clin Med       Date:  1978-02

7.  The release of beta-thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery.

Authors:  G Cella; O Vittadello; V Gallucci; A Girolami
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

8.  Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia.

Authors:  G Arepally; C Reynolds; A Tomaski; J Amiral; A Jawad; M Poncz; D B Cines
Journal:  Am J Clin Pathol       Date:  1995-12       Impact factor: 2.493

9.  Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR-PF4) in patients with cardiovascular disorders.

Authors:  G Cella; S I Colby; A D Taylor; L McCracken; A F Parisi; A A Sasahara
Journal:  Thromb Res       Date:  1983-03-01       Impact factor: 3.944

10.  Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity.

Authors:  D Stern; P Nawroth; J Marcum; D Handley; W Kisiel; R Rosenberg; K Stern
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more
  11 in total

1.  Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Authors:  M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

2.  Critical role of CD4 T cells in PF4/heparin antibody production in mice.

Authors:  Yongwei Zheng; Mei Yu; Anand Padmanabhan; Richard H Aster; Liudi Yuan; Renren Wen; Demin Wang
Journal:  Blood       Date:  2015-01-16       Impact factor: 22.113

3.  Heparin modifies the immunogenicity of positively charged proteins.

Authors:  Shalini L Chudasama; Benjamin Espinasse; Fred Hwang; Rui Qi; Manali Joglekar; Galyna Afonina; Mark R Wiesner; Ian J Welsby; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

Review 4.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

5.  Critical role for mouse marginal zone B cells in PF4/heparin antibody production.

Authors:  Yongwei Zheng; Mei Yu; Andrew Podd; Liudi Yuan; Debra K Newman; Renren Wen; Gowthami Arepally; Demin Wang
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

6.  Optimization of a murine immunization model for study of PF4/heparin antibodies.

Authors:  S Suvarna; R Qi; G M Arepally
Journal:  J Thromb Haemost       Date:  2009-02-24       Impact factor: 5.824

7.  Determinants of PF4/heparin immunogenicity.

Authors:  Shayela Suvarna; Benjamin Espinasse; Rui Qi; Rauova Lubica; Mortimer Poncz; Douglas B Cines; Mark R Wiesner; Gowthami M Arepally
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

8.  A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Authors:  Jason H Karnes; Robert M Cronin; Jerome Rollin; Alexander Teumer; Claire Pouplard; Christian M Shaffer; Carmelo Blanquicett; Erica A Bowton; James D Cowan; Jonathan D Mosley; Sara L Van Driest; Peter E Weeke; Quinn S Wells; Tamam Bakchoul; Joshua C Denny; Andreas Greinacher; Yves Gruel; Dan M Roden
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

9.  Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Authors:  Sanjay Khandelwal; Joann Ravi; Lubica Rauova; Alexandra Johnson; Grace M Lee; Jennifer B Gilner; Sreenivasulu Gunti; Abner L Notkins; Maragatha Kuchibhatla; Michael Frank; Mortimer Poncz; Douglas B Cines; Gowthami M Arepally
Journal:  Blood       Date:  2018-10-11       Impact factor: 25.476

10.  Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin.

Authors:  Satish Maharaj; Simone Chang; Karan Seegobin; James Morales; Agnes Aysola; Fauzia Rana; Marwan Shaikh
Journal:  Exp Hematol Oncol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.